These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 14534339)

  • 1. Chronic myeloid leukemia--advances in biology and new approaches to treatment.
    Goldman JM; Melo JV
    N Engl J Med; 2003 Oct; 349(15):1451-64. PubMed ID: 14534339
    [No Abstract]   [Full Text] [Related]  

  • 2. [Molecular signal transduction inhibitor for treatment of chronic myeloid leukemia].
    Meng FY
    Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(16):1082-4. PubMed ID: 16029561
    [No Abstract]   [Full Text] [Related]  

  • 3. [Chronic myelogenous leukaemia: recent progress in biology and therapeutic strategies].
    Turhan AG
    Bull Cancer; 2005 Jan; 92(1):75-82. PubMed ID: 15689327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment strategies for chronic myeloid leukemia].
    Jinnai I
    Rinsho Ketsueki; 2005 Jan; 46(1):1-6. PubMed ID: 16708910
    [No Abstract]   [Full Text] [Related]  

  • 5. Roots of clinical resistance to STI-571 cancer therapy.
    Barthe C; Cony-Makhoul P; Melo JV; Mahon JR
    Science; 2001 Sep; 293(5538):2163. PubMed ID: 11567109
    [No Abstract]   [Full Text] [Related]  

  • 6. Minimal residual disease in chronic myeloid leukemia.
    Löwenberg B
    N Engl J Med; 2003 Oct; 349(15):1399-401. PubMed ID: 14534331
    [No Abstract]   [Full Text] [Related]  

  • 7. Recent advancements in the treatment of chronic myelogenous leukemia.
    O'Dwyer ME; Mauro MJ; Druker BJ
    Annu Rev Med; 2002; 53():369-81. PubMed ID: 11818480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roots of clinical resistance to STI-571 cancer therapy.
    Hochhaus A; Kreil S; Corbin A; La Rosée P; Lahaye T; Berger U; Cross NC; Linkesch W; Druker BJ; Hehlmann R; Gambacorti- Passerini C; Corneo G; D'Incalci M
    Science; 2001 Sep; 293(5538):2163. PubMed ID: 11569495
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation.
    Caocci G; Atzeni S; Orrù N; Littera R; Culurgioni F; Marongiu F; La Nasa G
    Leuk Res; 2010 Jan; 34(1):e27-9. PubMed ID: 19748671
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term durability of molecular and chimerism responses in patients treated with imatinib for chronic myeloid leukemia relapse after allogeneic transplantation.
    Martín-Palanco V; Martínez F; Arqueros V; Torres A; Román-Gómez J
    Eur J Haematol; 2011 Aug; 87(2):182-5. PubMed ID: 21762210
    [No Abstract]   [Full Text] [Related]  

  • 11. Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: benign course responsive to imatinib with an RT-PCR advisory.
    Snyder DS; McMahon R; Cohen SR; Slovak ML
    Am J Hematol; 2004 Feb; 75(2):92-5. PubMed ID: 14755375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemia.
    Peggs K; Mackinnon S
    N Engl J Med; 2003 Mar; 348(11):1048-50. PubMed ID: 12637616
    [No Abstract]   [Full Text] [Related]  

  • 13. Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia.
    Carella AM
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):249-51. PubMed ID: 17338645
    [No Abstract]   [Full Text] [Related]  

  • 14. Secondary imatinib resistance associated with an aberrant bcr-abl fusion gene.
    Janssen JJ; Hochhaus A; van Oostveen JW; Waisfisz Q; Schuurhuis GJ; Ossenkoppele GJ
    Leukemia; 2004 May; 18(5):1020-1. PubMed ID: 15014529
    [No Abstract]   [Full Text] [Related]  

  • 15. New insights into the pathogenesis of chronic myeloid leukaemia: towards a path to cure.
    Thielen N; Ossenkoppele GJ; Schuurhuis GJ; Janssen JJ
    Neth J Med; 2011 Oct; 69(10):430-40. PubMed ID: 22058262
    [No Abstract]   [Full Text] [Related]  

  • 16. [Dual-color/dual-fusion interphase fluorescence in situ hybridization probe for monitoring tumor load during imatinib therapy for chronic myeloid leukemia].
    DU QF; Zhang S; Liu XL; Meng FY
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jan; 30(1):123-5. PubMed ID: 20118001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib and chronic-phase leukemias.
    Boros LG; Lee WN; Cascante M
    N Engl J Med; 2002 Jul; 347(1):67-8. PubMed ID: 12097546
    [No Abstract]   [Full Text] [Related]  

  • 18. Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era.
    Van Etten RA
    Leuk Res; 2004 May; 28 Suppl 1():S21-8. PubMed ID: 15036938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic myeloid leukemia.
    Sawyers CL
    N Engl J Med; 1999 Apr; 340(17):1330-40. PubMed ID: 10219069
    [No Abstract]   [Full Text] [Related]  

  • 20. Lack of Bcr-Abl point mutations in chronic myeloid leukemia patients in chronic phase before imatinib treatment is not predictive of response.
    Agirre X; Fontalba A; Andreu EJ; Odero MD; Larráyoz MJ; Montiel C; Calasanz MJ; Fernández-Luna JL; Prósper F
    Haematologica; 2003 Dec; 88(12):1425-6. PubMed ID: 14687999
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.